About SCOPE X
SCOPE X: Data Strategies & AI Innovation in Clinical Research
May 18–19, 2026 | Omni Boston Hotel at the Seaport | Boston, MA
SCOPE X is the newest addition to the trusted SCOPE Summit portfolio, designed for clinical research executives, data scientists, technology leaders, and innovators who want to go beyond surface-level conversations. Taking place May 18–19, 2026 at the Omni Boston Hotel at the Seaport, SCOPE X offers an intimate, two-day deep dive into how advanced data strategies and artificial intelligence (AI) are transforming clinical research.
What is SCOPE X?
SCOPE X is not another broad industry event; it’s a curated, in-person conference focused exclusively on the intersection of data, AI, and clinical research. Designed for senior leaders who want to move beyond theory, SCOPE X dives deep into the real-world implementation of AI, from building the right data and technology foundations to achieving measurable business impact.
The program features two concurrent tracks designed to meet the needs of both technical and strategic audiences:
AI-Ready Data & Technology Foundations Building the Data Backbone for Clinical AI Successful AI adoption in clinical research begins with robust data and technology infrastructure. This track explores how to prepare, manage, and scale data for AI applications, covering topics such as data structuring, interoperability, privacy, and security. Sessions will also examine cloud infrastructure, scalable pipelines, and tool integration to support advanced analytics, along with real-world lessons learned for building flexible, compliant, and future-ready systems.
AI Strategy, Business Value & Use Cases Turning AI Innovation into Business Value in Clinical Development This track focuses on the strategic, operational, and financial dimensions of AI adoption in clinical development. Senior leaders and cross-functional experts will present case studies on how AI accelerates timelines, improves decision-making, and delivers ROI. Discussions will address regulatory expectations, cost considerations, and how to identify fit-for-purpose applications that align innovation with organizational goals.
Together, these two tracks create a comprehensive platform for exploring how AI is reshaping the future of clinical trials, from data foundations to enterprise strategy.
The SCOPE X Experience
Unlike larger conferences, SCOPE X delivers:
- Highly interactive sessions and case studies that provide practical, actionable insights.
- Collaborative problem-solving where attendees work directly with peers to address shared challenges.
- High-value networking with clinical operations executives, clinical data leaders, AI specialists, technology providers, and regulatory experts.
- Boston is at the center of biopharma innovation, providing the ideal backdrop for meaningful exchange and industry advancement.
Attendees will explore topics including:
- Building AI-ready data strategies and technology foundations
- Applying agentic AI for trial transformation
- Leveraging real-world evidence for regulatory and market success
- Addressing AI governance, compliance, and ethical considerations
- Connecting business strategy with AI-driven ROI and operational efficiency
Why SCOPE X is Essential
The rapid evolution of AI and advanced analytics is reshaping clinical research, those who adapt now will lead to the next era of trials. SCOPE X is essential because it:
- Bridges innovation with business priorities, showing how AI creates measurable value in clinical development.
- Offers deep, specialized content not found at broader conferences.
- Equips attendees with actionable strategies for integrating AI into trial workflows while ensuring scalability, compliance, and organizational value.
With its intimate setting, expert-driven program, and focus on real-world applications, SCOPE X is the conference for clinical research leaders who are serious about advancing their data and AI capabilities.
If you’re ready to be at the forefront of clinical trials innovation, SCOPE X Boston is where you need to be in May 2026.
